Cargando…

Correction: Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance

Detalles Bibliográficos
Autores principales:	Yu, Yihua Bruce, Briggs, Katharine T., Taraban, Marc B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547613/ https://www.ncbi.nlm.nih.gov/pubmed/37561324 http://dx.doi.org/10.1007/s11095-023-03575-0

Ejemplares similares

Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance
por: Yu, Yihua Bruce, et al.
Publicado: (2023)

Why some people tolerate the second dose of a vaccine but not the first dose
por: Yu, Yihua Bruce, et al.
Publicado: (2022)

All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions
por: Bruce Yu, Yihua, et al.
Publicado: (2021)

Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics
por: Yu, Yihua Bruce, et al.
Publicado: (2021)

Excipient Innovation Through Precompetitive Research
por: Yu, Yihua Bruce, et al.
Publicado: (2021)

Sedimentation behavior of quality and freeze-damaged aluminum-adjuvanted vaccines by wNMR
por: Briggs, Katharine T., et al.
Publicado: (2023)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
por: Scicchitano, Francesca, et al.
Publicado: (2012)

Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
por: Giofrè, Chiara, et al.
Publicado: (2013)

Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
por: Schmider, Juergen, et al.
Publicado: (2018)

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (2020)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Pharmacovigilance: Paradise Lost, Regained or Postponed?
Publicado: (1995)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022)

Correction: HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention
Publicado: (2022)

Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study)
por: Lombardi, Niccolò, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events
Publicado: (2015)

Prevention of adverse events in the administration of drugs
por: Diano, G, et al.
Publicado: (2010)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Correction to: Machine Learning in Causal Inference: Application in Pharmacovigilance
por: Zhao, Yiqing, et al.
Publicado: (2022)

3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance
por: Vilar, Santiago, et al.
Publicado: (2015)

Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
por: Shrestha, Sunil, et al.
Publicado: (2021)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

Correction: Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Preventable adverse drug events: Descriptive epidemiology
por: Woo, Stephanie A., et al.
Publicado: (2020)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

Correction: Development of the Home-Based Fall Prevention Knowledge (HFPK) questionnaire to assess home-based fall prevention knowledge levels among older adults in China
por: Yang, Yuting, et al.
Publicado: (2022)

Conformational transition of a non-associative fluorinated amphiphile in aqueous solution. II. Conformational transition vs. supramolecular assembly
por: Taraban, Marc B., et al.
Publicado: (2019)

The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital
por: Vural, Fisun, et al.
Publicado: (2015)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India
por: Prakash, Jai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vagt8vl9tiik84rgqjd2rnpbj